A NOVEL COMBINATION TO DEFEAT LIFE THREATENING ORGANISM PSEUDOMONAS AERUGINOSA

• Main Authors: Lubna Jahanzeb (Author), Zahida Memon (Author), M. Owais Ismail (Author)
• Format: Book
• Published: ziauddin University, 2019-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary

There is global increase in resistance among bacterial species that lead to critical infections. Most of the Gram-negative bacteria are labelled as multi drug resistant. Among all different species, the Pseudomonas aeruginosa (P.aeruginosa) is one of the leading causes of life-threatening infections. It has become difficult to treat P.aeruginosa infections in current scenario as antimicrobial resistance has increased against antimicrobial drugs. So it has become a challenge to select optimal antibacterial drug or regimen for the patient treatment to prevent further resistance. Ceftolozane/tazobactam (C/T) is a novel combination of broad spectrum antibacterial agents that is 5th generation cephalosporin antibiotic and β-lactamase inhibitor. It is considered a best choice for the treatment of complicated infections including ventilator-associated bacterial pneumonia, nosocomial pneumonia, urinary tract infections and intra-abdominal infections. Ceftolozane/tazobactam possess sensitivity of about >90% against β-lactam resistant strains of P.aeruginosa. This combination is superior to various other antibiotics and antibacterial regimen so it has initiated a new chapter in an era of complicated infections. This review appraises the comparison of different broad spectrum antibiotics like levofloxacin, meropenem and tobramycin and antibacterial combinations including tazobactam/cefepime, ceftazidime/avibactam, tazobactam/piperacillin, with the Ceftolozane/tazobactam combination. This article also evaluates the effect of C/T if given in combination with other drugs like daptomycin, metronidazole and amikacin.

Item Description

2313-7371
2308-2593